JP2023540206A5 - - Google Patents
Info
- Publication number
- JP2023540206A5 JP2023540206A5 JP2023512718A JP2023512718A JP2023540206A5 JP 2023540206 A5 JP2023540206 A5 JP 2023540206A5 JP 2023512718 A JP2023512718 A JP 2023512718A JP 2023512718 A JP2023512718 A JP 2023512718A JP 2023540206 A5 JP2023540206 A5 JP 2023540206A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- pharmaceutical composition
- composition according
- anticancer agent
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070984P | 2020-08-27 | 2020-08-27 | |
| US63/070,984 | 2020-08-27 | ||
| PCT/US2021/047778 WO2022047051A1 (en) | 2020-08-27 | 2021-08-26 | Use of a dhodh inhibitor compound in combination cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540206A JP2023540206A (ja) | 2023-09-22 |
| JP2023540206A5 true JP2023540206A5 (cg-RX-API-DMAC7.html) | 2024-09-02 |
| JP7734742B2 JP7734742B2 (ja) | 2025-09-05 |
Family
ID=78000775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512718A Active JP7734742B2 (ja) | 2020-08-27 | 2021-08-26 | 癌併用療法におけるdhodh阻害剤化合物の利用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285365A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4203950B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734742B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230078997A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116847874B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023003493A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190511A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3063941T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022047051A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060390A1 (en) | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| CA3091792A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| BR112021012305A2 (pt) * | 2018-12-21 | 2021-10-05 | Les Laboratoires Servier Sas | Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2694829T3 (es) | 2013-02-25 | 2018-12-27 | Aurigene Discovery Technologies Limited | Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| CN106687139A (zh) * | 2014-07-14 | 2017-05-17 | 吉利德科学公司 | 用于治疗癌症的组合 |
| WO2016166761A1 (en) * | 2015-04-14 | 2016-10-20 | Tiltan Pharma Ltd. | Combination therapies and uses thereof in the treatment of cancer |
| CA3060390A1 (en) * | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| US20180369206A1 (en) * | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| CA3091792A1 (en) * | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| WO2019197269A1 (en) * | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
| KR20210003789A (ko) * | 2018-05-04 | 2021-01-12 | 포톨라 파마슈티컬스, 인코포레이티드 | 림프종을 치료하는 방법 |
| WO2020109625A1 (en) * | 2018-11-30 | 2020-06-04 | Fondazione Centro San Raffaele | Combined treatment of primary central nervous system lymphoma |
| BR112021012305A2 (pt) * | 2018-12-21 | 2021-10-05 | Les Laboratoires Servier Sas | Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas |
-
2021
- 2021-08-26 KR KR1020237004006A patent/KR20230078997A/ko active Pending
- 2021-08-26 US US18/015,396 patent/US20230285365A1/en active Pending
- 2021-08-26 WO PCT/US2021/047778 patent/WO2022047051A1/en not_active Ceased
- 2021-08-26 BR BR112023003493A patent/BR112023003493A2/pt unknown
- 2021-08-26 ES ES21783084T patent/ES3063941T3/es active Active
- 2021-08-26 EP EP21783084.3A patent/EP4203950B1/en active Active
- 2021-08-26 JP JP2023512718A patent/JP7734742B2/ja active Active
- 2021-08-26 CN CN202180052749.9A patent/CN116847874B/zh active Active
- 2021-08-26 CA CA3190511A patent/CA3190511A1/en active Pending